How Does Cheilbio’s (KOSDAQ:052670) P/E Compare To Its Industry, After Its Big Share Price Gain?

Cheilbio (KOSDAQ:052670) shares have continued recent momentum with a 45% gain in the last month alone. Zooming out, the annual gain of 188% knocks our socks off.

All else being equal, a sharp share price increase should make a stock less attractive to potential investors. In the long term, share prices tend to follow earnings per share, but in the short term prices bounce around in response to short term factors (which are not always obvious). The implication here is that deep value investors might steer clear when expectations of a company are too high. Perhaps the simplest way to get a read on investors’ expectations of a business is to look at its Price to Earnings Ratio (PE Ratio). A high P/E implies that investors have high expectations of what a company can achieve compared to a company with a low P/E ratio.

See our latest analysis for Cheilbio

How Does Cheilbio’s P/E Ratio Compare To Its Peers?

We can tell from its P/E ratio of 65.94 that there is some investor optimism about Cheilbio. As you can see below, Cheilbio has a higher P/E than the average company (27.5) in the pharmaceuticals industry.

KOSDAQ:A052670 Price Estimation Relative to Market, January 20th 2020
KOSDAQ:A052670 Price Estimation Relative to Market, January 20th 2020

That means that the market expects Cheilbio will outperform other companies in its industry. Shareholders are clearly optimistic, but the future is always uncertain. So investors should delve deeper. I like to check if company insiders have been buying or selling.

How Growth Rates Impact P/E Ratios

P/E ratios primarily reflect market expectations around earnings growth rates. When earnings grow, the ‘E’ increases, over time. That means even if the current P/E is high, it will reduce over time if the share price stays flat. And as that P/E ratio drops, the company will look cheap, unless its share price increases.

Cheilbio’s earnings made like a rocket, taking off 94% last year. Even better, EPS is up 20% per year over three years. So you might say it really deserves to have an above-average P/E ratio.

Don’t Forget: The P/E Does Not Account For Debt or Bank Deposits

Don’t forget that the P/E ratio considers market capitalization. That means it doesn’t take debt or cash into account. Theoretically, a business can improve its earnings (and produce a lower P/E in the future) by investing in growth. That means taking on debt (or spending its cash).

Spending on growth might be good or bad a few years later, but the point is that the P/E ratio does not account for the option (or lack thereof).

So What Does Cheilbio’s Balance Sheet Tell Us?

Cheilbio has net cash of ₩11b. That should lead to a higher P/E than if it did have debt, because its strong balance sheets gives it more options.

The Verdict On Cheilbio’s P/E Ratio

With a P/E ratio of 65.9, Cheilbio is expected to grow earnings very strongly in the years to come. The excess cash it carries is the gravy on top its fast EPS growth. To us, this is the sort of company that we would expect to carry an above average price tag (relative to earnings). What we know for sure is that investors have become much more excited about Cheilbio recently, since they have pushed its P/E ratio from 45.5 to 65.9 over the last month. If you like to buy stocks that have recently impressed the market, then this one might be a candidate; but if you prefer to invest when there is ‘blood in the streets’, then you may feel the opportunity has passed.

When the market is wrong about a stock, it gives savvy investors an opportunity. People often underestimate remarkable growth — so investors can make money when fast growth is not fully appreciated. We don’t have analyst forecasts, but you might want to assess this data-rich visualization of earnings, revenue and cash flow.

Of course, you might find a fantastic investment by looking at a few good candidates. So take a peek at this free list of companies with modest (or no) debt, trading on a P/E below 20.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.